Compared with the non-CKD group, a higher proportion of patients in the CKD and ESRD groups took ACEIs/ARBs, beta-2 blockers, CCBs, warfarin, antiplatelet drugs, diuretics, alpha-glucosidase inhibitors, DPP-4is, and insulin. The gene discussed is GAA; the disease is chronic kidney disease.